Retrieve available abstracts of 91 articles: HTML format
Single Articles
September 2025
JIANG C, He X, Chen X, Huang J, et al Lactate accumulation drives hepatocellular carcinoma metastasis through
facilitating tumor-derived exosome biogenesis by Rab7A lactylation.
Cancer Lett. 2025;627:217636. PubMedAbstract available
August 2025
YANG Y, Li Z, Yu X, Zheng Y, et al WDR11-DT enhances radiosensitivity via promoting PARP1 degradation and homologous
recombination deficiency.
Cancer Lett. 2025;625:217757. PubMedAbstract available
July 2025
LUCA AC, Kurnaeva M, John DK, Machtinger M, et al Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma.
Cancer Lett. 2025;623:217733. PubMedAbstract available
JIANG M, Zhang K, Wei G, Qi F, et al HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote
chemoresistance in LUAD.
Cancer Lett. 2025;623:217716. PubMedAbstract available
May 2025
WADE WEI TY, Hsia JY, Yang TY, Huang YX, et al Mechanistic Insights into CLNS1A-Mediated Chemoresistance and Tumor Progression
in Non-small Cell Lung Cancer.
Cancer Lett. 2025 May 7:217783. doi: 10.1016/j.canlet.2025.217783. PubMedAbstract available
April 2025
JIANG J, Chen H, Zhao C, Li T, et al PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2
polarization of tumor-associated macrophages in lung adenocarcinoma.
Cancer Lett. 2025;616:217584. PubMedAbstract available
LIN H, Hua J, Gong Z, Chen M, et al Multimodal radiopathological integration for prognosis and prediction of adjuvant
chemotherapy benefit in resectable lung adenocarcinoma: A multicentre study.
Cancer Lett. 2025;616:217557. PubMedAbstract available
MO Y, Qin Y, Li P, Wu M, et al Thyroxine alleviates interstitial lung disease induced by combined radiotherapy
and immunotherapy.
Cancer Lett. 2025;615:217504. PubMedAbstract available
XIAO X, Huang L, Li M, Zhang Q, et al Intersection between lung cancer and neuroscience: opportunities and challenges.
Cancer Lett. 2025 Apr 5:217701. doi: 10.1016/j.canlet.2025.217701. PubMedAbstract available
March 2025
PENG X, Yang R, Wang C, Peng W, et al The YTHDF3-DT/miR-301a-3p /INHBA axis attenuates autophagy-dependent ferroptosis
in lung adenocarcinoma.
Cancer Lett. 2025;613:217503. PubMedAbstract available
LI J, Xu S, Zhan Y, Lv X, et al CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung
cancer through the miR-145/HK2 pathway.
Cancer Lett. 2025 Mar 14:217639. doi: 10.1016/j.canlet.2025.217639. PubMedAbstract available
ZHAO L, Ren Y, Gong C, Xiong S, et al RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via
a multiomics analysis.
Cancer Lett. 2025;612:217462. PubMedAbstract available
TANG X, Hu J, Guo R, Wang Y, et al RET-AREAL: A multi-center, real-world data analysis on the efficacy of
pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs.
Cancer Lett. 2025;612:217455. PubMedAbstract available
February 2025
FU R, Zhang C, Song MM, Gao X, et al A single-cell map of patients with non-small cell lung cancer harboring
rare-driver mutations after anti-PD-1 treatment.
Cancer Lett. 2025;616:217595. PubMedAbstract available
January 2025
HUANG M, Sun J, Jiang Q, Zhao X, et al CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and
Chemoresistance.
Cancer Lett. 2025;612:217494. PubMedAbstract available
December 2024
YU JJ, Zhou DD, Cui B, Zhang C, et al Corrigendum to <[
Cancer Letters 474 (2020) 23-35]>.
Cancer Lett. 2024 Dec 30:217434. doi: 10.1016/j.canlet.2024.217434. PubMed
DONG XD, Zhang M, Teng QX, Lei ZN, et al Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing
cancer cells: In vitro and in vivo studies.
Cancer Lett. 2024;607:217309. PubMedAbstract available
HUANG S, Chung JY, Li C, Wu Y, et al Corrigendum to "Cellular dynamics of tumor microenvironment driving immunotherapy
resistance in non-small-cell lung carcinoma" [Cancer Lett. 604 (2024) 217272].
Cancer Lett. 2024 Dec 27:217425. doi: 10.1016/j.canlet.2024.217425. PubMed
YAMAMOTO G, Tanaka K, Kamata R, Saito H, et al WEE1 Confers Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer.
Cancer Lett. 2024 Dec 24:217414. doi: 10.1016/j.canlet.2024.217414. PubMedAbstract available
SUAY G, Garcia-Canaveras JC, Aparisi F, Garcia J, et al Immune checkpoint inhibitors as first-line treatment for brain metastases in
stage IV NSCLC patients without driver mutations.
Cancer Lett. 2024;606:217317. PubMedAbstract available
NERLAKANTI N, McGuire JJ, Bishop RT, Nasr MM, et al Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for
pulmonary metastasis.
Cancer Lett. 2024;606:217302. PubMedAbstract available
November 2024
LI J, Wang X, Cao G, Wu Y, et al CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and
humanized murine models.
Cancer Lett. 2024;605:217305. PubMedAbstract available
ZHAO Y, Zhang D, Meng B, Zhang Y, et al Integrated proteomic and glycoproteomic analysis reveals heterogeneity and
molecular signatures of brain metastases from lung adenocarcinomas.
Cancer Lett. 2024;605:217262. PubMedAbstract available
GE H, Malsiu F, Gao Y, Losmanova T, et al Inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing
mitochondrial GSH catabolism.
Cancer Lett. 2024 Nov 28:217353. doi: 10.1016/j.canlet.2024.217353. PubMedAbstract available
ZHANG J, Wu Q, Zhu L, Xie S, et al Corrigendum to "SERPINE2/PN-1 regulates the DNA damage response and
radioresistance by activating ATM in lung cancer" [Cancer Lett. 524 (2022)
268-283].
Cancer Lett. 2024 Nov 23:217337. doi: 10.1016/j.canlet.2024.217337. PubMed
October 2024
PLAUGHER DR, Childress AR, Gosser CM, Esoe DP, et al Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung
cancer.
Cancer Lett. 2024 Oct 4:217281. doi: 10.1016/j.canlet.2024.217281. PubMedAbstract available
WU J, Chen Y, Zou H, Xu K, et al 6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by
inhibiting the AMPK pathway in lung adenocarcinoma cells.
Cancer Lett. 2024;601:217177. PubMedAbstract available
September 2024
HUANG L, Liu X, Chen Q, Yang J, et al TGF-beta-induced lncRNA TBUR1 promotes EMT and metastasis in lung adenocarcinoma via
hnRNPC-mediated GRB2 mRNA stabilization.
Cancer Lett. 2024;600:217153. PubMedAbstract available
WU J, Zhao Q, Chen S, Xu H, et al NSUN4-mediated m5C modification of circERI3 promotes lung cancer development by
altering mitochondrial energy metabolism.
Cancer Lett. 2024 Sep 25:217266. doi: 10.1016/j.canlet.2024.217266. PubMedAbstract available
HUANG S, Yat-Fai Chung J, Li C, Wu Y, et al Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in
Non-Small-Cell Lung Carcinoma.
Cancer Lett. 2024 Sep 24:217272. doi: 10.1016/j.canlet.2024.217272. PubMedAbstract available
GARGALIONIS AN, Papavassiliou KA, Basdra EK, Papavassiliou AG, et al Exploiting tumor mechanomedicine for lung cancer treatment.
Cancer Lett. 2024;604:217229. PubMed
GANG X, Yan J, Li X, Shi S, et al Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current
Evidence and Future Directions.
Cancer Lett. 2024 Sep 9:217241. doi: 10.1016/j.canlet.2024.217241. PubMedAbstract available
LA VECCHIA S, Fontana S, Salaroglio IC, Anobile DP, et al Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung
cancer to anti-PD-1/PD-L1 immunotherapy.
Cancer Lett. 2024;604:217221. PubMedAbstract available
WEI X, Uchibori K, Kondo N, Utsumi T, et al MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged
non-small cell lung cancer.
Cancer Lett. 2024 Sep 5:217220. doi: 10.1016/j.canlet.2024.217220. PubMedAbstract available
SUN SY Is tumor microenvironment important for targeted therapy in lung cancer?
Cancer Lett. 2024 Sep 3:217203. doi: 10.1016/j.canlet.2024.217203. PubMed
XUE R, Li X, Yang L, Yang M, et al Evaluation and integration of cell-free DNA signatures for detection of lung
cancer.
Cancer Lett. 2024 Sep 2:217216. doi: 10.1016/j.canlet.2024.217216. PubMedAbstract available
August 2024
LI J, Bai M, Jia W, Zhai X, et al Irradiated tumor cell-released microparticles enhance the therapeutic efficacy of
PD-1 inhibitors by promoting M1-TAMs polarization in NSCLC brain metastases.
Cancer Lett. 2024;598:217133. PubMedAbstract available
LU Y, Sun Y, Zhang J, Kong M, et al The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune
checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
Cancer Lett. 2024;596:217020. PubMedAbstract available
FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients
80 years or older: A retrospective cohort study.
Cancer Lett. 2024;596:217001. PubMedAbstract available
KIM YJ, Lee M, Kim EH, Lee S, et al Real-world incidences and risk factors of immune-related adverse events in
patients treated with immune checkpoint inhibitors: A nationwide retrospective
cohort study.
Cancer Lett. 2024;596:216998. PubMedAbstract available
CHOW Z, Johnson J, Chauhan A, Jeong JC, et al Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity
of metastatic pancreatic neuroendocrine tumor.
Cancer Lett. 2024;596:216993. PubMedAbstract available
July 2024
HUANG L, Wang J, Wang X, Zheng S, et al Sulforaphane suppresses bladder cancer metastasis via blocking actin
nucleation-mediated pseudopodia formation.
Cancer Lett. 2024 Jul 29:217145. doi: 10.1016/j.canlet.2024.217145. PubMedAbstract available
LIU M, Gu L, Zhang Y, Li Y, et al LKB1 inhibits telomerase activity resulting in cellular senescence through
histone lactylation in lung adenocarcinoma.
Cancer Lett. 2024;595:217025. PubMedAbstract available
NAKAMURA R, Yamada T, Tokuda S, Morimoto K, et al Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR
inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Cancer Lett. 2024;598:217124. PubMedAbstract available
SINGH D, Qiu Z, Jonathan SM, Fa P, et al PP2A B55alpha Inhibits Epithelial-Mesenchymal Transition Via Regulation of Slug
Expression in Non-Small Cell Lung Cancer.
Cancer Lett. 2024 Jul 8:217110. doi: 10.1016/j.canlet.2024.217110. PubMedAbstract available
LI X, Shang S, Wu M, Song Q, et al Gut microbial metabolites in lung cancer development and immunotherapy: Novel
insights into gut-lung axis.
Cancer Lett. 2024;598:217096. PubMedAbstract available
SHU M, Huang L, Chen Y, Wang Y, et al Identification of a DNA-methylome-based signature for prognosis prediction in
driver gene-negative lung adenocarcinoma.
Cancer Lett. 2024;593:216835. PubMedAbstract available
June 2024
GUGNONI M, Lorenzini E, Torricelli F, Donati B, et al Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC
translation in malignant pleural mesothelioma.
Cancer Lett. 2024;592:216950. PubMedAbstract available
HE Q, Qu M, Xu C, Wu L, et al Smoking-induced CCNA2 expression promotes lung adenocarcinoma tumorigenesis by
boosting AT2/AT2-like cell differentiation.
Cancer Lett. 2024;592:216922. PubMedAbstract available
XU Z, Shi Y, Zhu L, Luo J, et al Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell
lung cancer by promoting endoplasmic reticulum stress and mitochondrial
dysfunction.
Cancer Lett. 2024 Jun 21:217075. doi: 10.1016/j.canlet.2024.217075. PubMedAbstract available
GUO W, Qiao T, Li H, Zhao Y, et al Peripheral CD8(+)PD-1(+) T cells as novel biomarker for neoadjuvant
chemoimmunotherapy in humanized mice of non-small cell lung cancer.
Cancer Lett. 2024;597:217073. PubMedAbstract available
LIU X, Zheng W, Zhang L, Cao Z, et al Corrigendum to "Arginine methylation-dependent cGAS stability promotes non-small
cell lung cancer cell proliferation" [Cancer Lett. 586 (2024) 216707/CAN_216707].
Cancer Lett. 2024 Jun 5:217003. doi: 10.1016/j.canlet.2024.217003. PubMed
ZHENG L, Shen J, Chen Y, Lin J, et al FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2.
Cancer Lett. 2024;591:216848. PubMedAbstract available
May 2024
ZHANG L, Xu Y, Cheng Z, Zhao J, et al The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung
cancer via ferroptosis.
Cancer Lett. 2024;595:217000. PubMedAbstract available
BOSSE Y, Dasgupta A, Abadier M, Guthrie V, et al Prognostic implication of methylation-based circulating tumor DNA detection prior
to surgery in stage I non-small cell lung cancer.
Cancer Lett. 2024;594:216984. PubMedAbstract available
JIANG Y, Li S, Ramesh R Identification of SMARCAL1 as a molecular target for small cell lung cancer
treatment.
Cancer Lett. 2024 May 10:216932. doi: 10.1016/j.canlet.2024.216932. PubMed
CHEN X, Yuan M, Zhong T, Wang M, et al LILRB2 Inhibition Enhances Radiation Sensitivity in Non-Small Cell Lung Cancer by
Attenuating Radiation-Induced Senescence.
Cancer Lett. 2024 May 3:216930. doi: 10.1016/j.canlet.2024.216930. PubMedAbstract available
WANG PS, Liu Z, Sweef O, Saeed AF, et al Hexavalent chromium exposure activates the non-canonical nuclear factor kappa B
pathway to promote immune checkpoint protein programmed death-ligand 1 expression
and lung carcinogenesis.
Cancer Lett. 2024;589:216827. PubMedAbstract available
YU T, Liu Z, Tao Q, Xu X, et al Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune
microenvironment reprogramming.
Cancer Lett. 2024;589:216824. PubMedAbstract available
LUO S, Luo Y, Wang Z, Yin H, et al Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung
adenocarcinoma.
Cancer Lett. 2024;589:216811. PubMedAbstract available
April 2024
SUN BB, Wang GZ, Han SC, Yang FY, et al Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1
in small cell lung cancer.
Cancer Lett. 2024 Apr 30:216929. doi: 10.1016/j.canlet.2024.216929. PubMedAbstract available
YOKOTA E, Iwai M, Yukawa T, Naomoto Y, et al Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma:
a promising tool for personalized medicine and developing novel therapeutic
strategies.
Cancer Lett. 2024;588:216816. PubMedAbstract available
MOON JW, Hong BJ, Kim SK, Park MS, et al Systematic identification of a synthetic lethal interaction in brain-metastatic
lung adenocarcinoma.
Cancer Lett. 2024;588:216781. PubMedAbstract available
LUO J, Cheng K, Ji X, Gao C, et al Anlotinib enhanced CD8(+) T cell infiltration via induction of CCL5 improves the
efficacy of PD-1/PD-L1 blockade therapy in lung cancer.
Cancer Lett. 2024;591:216892. PubMedAbstract available
MORIMOTO K, Yamada T, Hirai S, Katayama Y, et al AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS
G12C-mutant tumor cells.
Cancer Lett. 2024;587:216692. PubMedAbstract available
GAO GB, Chen L, Pan JF, Lei T, et al LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce
ferroptosis in non-small cell lung cancer.
Cancer Lett. 2024 Apr 2:216826. doi: 10.1016/j.canlet.2024.216826. PubMedAbstract available
HAO Z, Xin Z, Chen Y, Shao Z, et al JAML promotes the antitumor role of tumor-resident CD8(+) T cells by facilitating
their innate-like function in human lung cancer.
Cancer Lett. 2024 Apr 1:216839. doi: 10.1016/j.canlet.2024.216839. PubMedAbstract available
March 2024
ZHANG E, Sun Q, Zhang C, Ma H, et al Comprehensive functional interrogation of susceptibility loci in GWASs identified
KIAA0391 as a novel oncogenic driver via regulating pyroptosis in NSCLC.
Cancer Lett. 2024;585:216646. PubMedAbstract available
JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al Unlocking c-MET: A comprehensive journey into targeted therapies for breast
cancer.
Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780. PubMedAbstract available
MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are
sensitive to synergistic combination PARP inhibitor treatment.
Cancer Lett. 2024;584:216608. PubMedAbstract available
February 2024
HAN R, Lin C, Lu C, Wang Y, et al Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to
overcome resistance in non-small cell lung cancer.
Cancer Lett. 2024;588:216762. PubMedAbstract available
LIU X, Zheng W, Zhang L, Cao Z, et al Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer
cell proliferation.
Cancer Lett. 2024 Feb 6:216707. doi: 10.1016/j.canlet.2024.216707. PubMedAbstract available
LU X, Yu R, Li Z, Yang M, et al JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes
RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
Cancer Lett. 2024;582:216517. PubMedAbstract available
LIN S, He C, Song L, Sun L, et al Exosomal lncCRLA is predictive for the evolvement and development of lung
adenocarcinoma.
Cancer Lett. 2024;582:216588. PubMedAbstract available
BISWAS U, Roy R, Ghosh S, Chakrabarti G, et al The interplay between autophagy and apoptosis: its implication in lung cancer and
therapeutics.
Cancer Lett. 2024 Feb 1:216662. doi: 10.1016/j.canlet.2024.216662. PubMedAbstract available
January 2024
SUN J, Dong M, Xiang X, Zhang S, et al Notch signaling and targeted therapy in non-small cell lung cancer.
Cancer Lett. 2024 Jan 30:216647. doi: 10.1016/j.canlet.2024.216647. PubMedAbstract available
SUI Q, Hu Z, Liang J, Lu T, et al Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect
of metformin in treating lung adenocarcinoma.
Cancer Lett. 2024;581:216497. PubMedAbstract available
ZHANG H, Li S, Zhou R, Dong T, et al SRCAP complex promotes lung cancer progression by reprograming the oncogenic
transcription of Hippo-YAP/TAZ signaling pathway.
Cancer Lett. 2024;585:216667. PubMedAbstract available
ZHOU X, Jia Y, Mao C, Liu S, et al Small extracellular vesicles: Non-negligible vesicles in tumor progression,
diagnosis, and therapy.
Cancer Lett. 2024;580:216481. PubMedAbstract available
December 2023
YANG Y, Wang J, Wang J, Zhao X, et al Unrevealing the therapeutic benefits of radiotherapy and consolidation
immunotherapy using ctDNA-defined tumor clonality in unresectable locally
advanced non-small cell lung cancer.
Cancer Lett. 2023 Dec 13:216569. doi: 10.1016/j.canlet.2023.216569. PubMedAbstract available
MENG Y, Lin W, Wang N, Wei X, et al USP7-mediated ERbeta stabilization mitigates ROS accumulation and promotes
osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung
carcinoma.
Cancer Lett. 2023 Dec 12:216587. doi: 10.1016/j.canlet.2023.216587. PubMedAbstract available
XIE Y, Zhang L, Wang L, Chen B, et al EphB1 promotes the differentiation and maturation of dendritic cells in non-small
cell lung cancer.
Cancer Lett. 2023;582:216567. PubMedAbstract available
YUAN Y, Li Y, Wu X, Bo J, et al POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis.
Cancer Lett. 2023 Dec 5:216526. doi: 10.1016/j.canlet.2023.216526. PubMedAbstract available
KONG R, Wei W, Man Q, Chen L, et al Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis
of cancer stem cells from hepatocellular carcinoma.
Cancer Lett. 2023;578:216442. PubMedAbstract available
November 2023
ZHOU Y, Guo Y, Ran M, Shan W, et al Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase
a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma
cell killing.
Cancer Lett. 2023;577:216425. PubMedAbstract available
NAMKAEW J, Zhang J, Yamakawa N, Hamada Y, et al Repositioning of mifepristone as an integrated stress response activator to
potentiate cisplatin efficacy in non-small cell lung cancer.
Cancer Lett. 2023 Nov 28:216509. doi: 10.1016/j.canlet.2023.216509. PubMedAbstract available
CAI S, Zhang B, Huang C, Deng Y, et al CTRP6 protects against ferroptosis to drive lung cancer progression and
metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway.
Cancer Lett. 2023;579:216465. PubMedAbstract available
LI B, Chen Q, Feng Y, Wei T, et al Glucose restriction induces AMPK-SIRT1-mediated circadian clock gene Per
expression and delays NSCLC progression.
Cancer Lett. 2023;576:216424. PubMedAbstract available
October 2023
HUA WJ, Yeh H, Lin ZH, Tseng AJ, et al Ganoderma microsporum immunomodulatory protein as an extracellular epidermal
growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer
cells.
Cancer Lett. 2023;578:216458. PubMedAbstract available
ZHANG Q, Zheng L, Bai Y, Su C, et al ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21(HRAS)
splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade.
Cancer Lett. 2023 Oct 9:216426. doi: 10.1016/j.canlet.2023.216426. PubMedAbstract available
September 2023
LIU X, Li R, Chen X, Yao J, et al SYT7 is a key player in increasing exosome secretion and promoting angiogenesis
in non-small-cell lung cancer.
Cancer Lett. 2023 Sep 27:216400. doi: 10.1016/j.canlet.2023.216400. PubMedAbstract available